More than unit-dose. We bring novel products to the patients who need them.
Kesin emerged from the struggle to balance healthcare quality, accessibility, and cost. We reinvent established therapies and develop differentiated medicines — moving them efficiently from concept to commercialization for underserved conditions.
Solutions
From specialty NDA 505(b)(2) brand products to unit-dose formulations, our portfolio is built to address adherence challenges and improve patient outcomes.
Partnerships
We collaborate with a global network of trusted developers and healthcare stakeholders — payers, PBMs, GPOs, IDNs, and trade partners — creating holistic value across the system.
Bringing products to market
Our efficient commercialization model streamlines go-to-market timelines, delivering new formulations faster to providers and patients who need them.
A growing portfolio across specialty and unit-dose.
The Kesin portfolio is carefully selected to address patient adherence challenges, supported by in-house manufacturing and distribution in Oldsmar, Florida.
- ✓ Specialty NDA 505(b)(2) brand products that materially impact patient access
- ✓ Unit-dose formulations that promote adherence, accessibility, and safety
- ✓ NABP-accredited distribution and complete in-house manufacturing capabilities
Let's reinvent what's possible — together.
Whether you're a provider, a development partner, or a distributor, our team is ready to connect.
Contact Kesin Pharma →